Dawn I. Velligan, PhD

  • 13Articles
  • 70.1KReads
  • 1999–2023Active
  • 20Collaborators
  • 467Citations

About

Dawn I. Velligan, PhD, is affiliated with the Division of Schizophrenia and Related Disorders in the Department of Psychiatry and Behavioral Sciences at The University of Texas Health Science Center at San Antonio. With publications spanning from 1999 to 2023, Velligan has contributed extensively to topics including schizophrenia, schizoaffective disorders, bipolar disorder, neurology, and patient care. Her work addresses treatment landscapes, symptomatology, adherence challenges, cognitive impairment, and therapy optimization in schizophrenia. She has frequently collaborated with authors such as Sanjai Rao, Alexander L. Miller, and Peter J. Weiden.

Publications

JCP
The Emerging Treatment Landscape in Schizophrenia
Commentary

The Emerging Treatment Landscape in Schizophrenia

January 18, 2023

This article provides an overview of emerging therapies poised to transform the treatment paradigm for patients with living with schizophrenia.
,
JCP
Schizophrenia: Salient Symptoms and Pathophysiology
Commentary

Schizophrenia: Salient Symptoms and Pathophysiology

January 18, 2023

This article notes the distinction between positive and negative schizophrenic symptoms and provides an updated overview of disease pathophysiology.
JCP
Adverse Events and Treatment Adherence in Schizophrenia
Commentary

Adverse Events and Treatment Adherence in Schizophrenia

January 18, 2023

This article examines the effects of treatment-related adverse events on adherence to medication and strategies to improve adherence in practice.
,
JCP
The Epidemiology and Global Burden of Schizophrenia
Commentary

The Epidemiology and Global Burden of Schizophrenia

January 18, 2023

This article explores the costs and burden of schizophrenia and provides an overview of disease prevalence, incidence, and trends over time.
,
JCP
Optimizing Therapy Selection, Sequencing in Schizophrenia
Commentary

Optimizing Therapy Selection, Sequencing in Schizophrenia

January 18, 2023

This article summarizes the current treatment landscape in schizophrenia, along with contexts in which agents should be prescribed.
,
JCP
Defining and Achieving Treatment Recovery in Schizophrenia
Commentary

Defining and Achieving Treatment Recovery in Schizophrenia

January 18, 2023

This article defines treatment recovery in schizophrenia and summarizes strategies clinicians can pursue to improve patient outcomes.
,
JCP
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
Insights

Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video

January 14, 2023

Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
,
JCP
Shared Decision Making in Schizophrenia Treatment Video
Insights

Shared Decision Making in Schizophrenia Treatment Video

January 14, 2023

Although there are now multiple medications available to treat schizophrenia, many gaps still exist as a barrier to treatment success resulting in lower quality of life for this patient...
,
JCP
Original Research

The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

June 24, 2015

, , , et al
JCP
Article

Adherence Problems in Patients with Serious and Persistent Mental Illness

July 31, 2009

, , , et al
JCP
Original Research

Cognitive Functioning in Schizophrenia: A Consensus Statement on Its Role in the Definition and Evaluation of Effective Treatments for the Illness

March 1, 2004

, , , et al
JCP
Original Research

The Effectiveness of Quetiapine Versus Conventional Antipsychotics in Improving Cognitive and Functional Outcomes in Standard Treatment Settings

May 15, 2003

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe